Nurix Therapeutics, Inc. (NRIX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Nurix Therapeutics, Inc. (NRIX) closed at USD 23.67 on 2026-10-14, a change of +98.9 % over the past year, with a market capitalization of USD 2.73B.

Nurix Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Nurix Therapeutics, Inc. key figures

Previous close

USD 23.67 (2026-10-14)

1-year change

+98.9 %

Market cap

USD 2.73B

Enterprise value

USD 1.74B

P/E ratio (trailing)

9.11

P/E ratio (forward)

-15.56

EPS (trailing)

2.74

EPS (forward)

-1.60

PEG ratio

n/a

Price to book

2.81

Revenue growth

8,426.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.33

Employees

317

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc. for co-development and co-commercialization of multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Nurix Therapeutics, Inc. and compare it with other stocks.